Rheumatology
| Rheumatoid Arthritis
Rheumatology
Rheumatoid Arthritis

Stable versus tapered and withdrawn treatment with tumor necrosis factor inhibitor in rheumatoid arthritis remission: a randomized, open-label, phase 4, non-inferiority trial

book_2 Source: ACR Convergence 2020 - Oral session summaries - Abs #2010
calendar_today Published on Medfyle: November 2020
import_contacts 7 min
headphones 4 min

In this medfyle

Exert commentary by Kevin Winthrop, MD

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Acknowledgements
Read more arrow_downward Hide arrow_upward

This is a highlights summary of an oral session given at the ACR Convergence 2020 and presented by:

Siri Lillegraven, MD, PhD
Diakonhjemmet Hospital
Oslo, Norway

The presenting authors of the original session had no part in the creation of this conference highlights summary.

Kevin Winthrop, MD
Oregon Health & Science University, Portland, OR, USA

The content is produced by Infomedica, an approved ACR education partner. The summary text was drafted by Marie Farrow, and reviewed by Alessia Alunno, MD, PhD, an independent external expert, and approved by Atul Deodhar, MD, MRCP, the scientific editor of the program.
This activity is included in the ACR's Education Partner program. Independent reporting and the viewpoints expressed are those of Infomedica and its affiliates and do not represent the ACR.

About the Expert
Read more arrow_downward Hide arrow_upward

Kevin Winthrop, MD
Oregon Health & Science University, Portland, OR, USA

Kevin L. Winthrop is Professor of Infectious Diseases and Ophthalmology at the School of Medicine and a Professor of Public Health at the OHSU-PSU School of Public Health at Oregon Health & Science University (OHSU) in Portland, OR, USA.

Dr. Winthrop received his undergraduate degree in biology from Yale University, New Haven, CT, USA and his MD from OHSU. He completed his internal medicine residency training at Legacy Emanuel Hospital, Portland, OR. He then completed an infectious disease epidemiology fellowship at the US Centers for Disease Control and Prevention. In 2003, Dr. Winthrop was conferred a Master in Public Health from the University of California, Berkley, CA, USA. In 2006, Dr. Winthrop returned to OHSU as Assistant Professor before progressing to his current appointment in 2012.

A former infectious disease epidemiologist in the Division of Tuberculosis Elimination at the US Centers for Disease Control and Prevention (CDC), Dr Winthrop has co-authored over 200 publications, many regarding the epidemiologic and clinical aspects of opportunistic infections associated with immune-mediated inflammatory diseases, particularly those related to biologic immunosuppressive therapies.

As a primary or senior investigator in many clinical or epidemiologic studies in these fields, he has collaborated closely with the rheumatology community in the evaluation and prevention of opportunistic infections in that setting. In addition, he is also a member of the graduate faculty at OHSU where he mentors public health students, medical students, and physicians in post-graduate training.

References
Read more arrow_downward Hide arrow_upward

1. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79(6):685–99.


Feedback